Sat, Jan 31, 2015, 12:16 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

SAVIENT PHARM INC Message Board

staccani 215 posts  |  Last Activity: 9 hours ago Member since: Sep 24, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Prostate cancer may originate from distinct cell types, resulting in the heterogeneity of this disease. Galectin-3 (Gal-3) and androgen receptor (AR) have been reported to play important roles in the progression of prostate cancer, and their heterogeneous expressions might be associated with different cancer subtypes. Our study found that in various prostate cancer cell lines Gal-3 expression was always opposite to AR expression and other luminal cell markers but consistent with basal cell markers including glutathione S-transferase-π and Bcl-2. This expression pattern was confirmed in human prostate cancer tissues. Our results also showed that prostate cancer cells positive with basal cell markers were more aggressive. Downregulation of Gal-3 expression resulted in increased apoptotic potential and decreased metastasis potential of prostate cancer cells. Our findings demonstrate for the first time that Gal-3 may serve as a new marker for basal characteristics of prostate cancer epithelium. This study helps us to better understand the heterogeneity of prostate cancer. The clinical significance of this study lies in the application of Gal-3 to distinguish prostate cancer subtypes and improve treatment efficacy with designed personalized therapy.

    Sentiment: Strong Buy

  • Just go and check all his posts. Not worth even replying to him.

  • Reply to

    Expectations

    by surplus.value Jan 8, 2015 2:37 PM
    staccani staccani 11 hours ago Flag

    well done surplus value. Since you last prediction of no price increase on Jan 9th PPS has gone up 200%.
    I am suprised that the HF paying you, still hasn't fired you. But do not give up hope, he will. LOL

  • Reply to

    $100 pps

    by frankiefaithful829 13 hours ago
    staccani staccani 12 hours ago Flag

    Not sure for how long you have been doing tour DD on BGMD, but it looks like you had not much value from your time:
    1) there are ca 30M people in the world living with chronic heart failure (just google it, it takes 5 minutes, not 5 years)
    2) it seems you have overlooked the at least 20 studies published in the last 2 months where strong evidence of efficacy of Gal 3 as predictive of short term hospitalization and long term death for people suggering of HF. Without evidence of efficacy it would not sell, as it did not sell, much since 2013 in Europe, with evidence of efficacy as biomarker it will become a standard test with time.
    3) Gal 3 is also effective biomarker for other conditions
    Put the 3 above together (not difficult and it would not require much time) and maybe you will realize that 2015 and beyond will look very different compared to 2013 for BGMD

    Sentiment: Strong Buy

  • Reply to

    $100 pps

    by frankiefaithful829 13 hours ago
    staccani staccani 13 hours ago Flag

    One of the possile application of Gal 3 automated test is in the Heart Failure patients. There are 30M people suffering from HF globally. If Gal 3 test becomes a standard test as it should, BGMD has basically no competition. At $30 x 2 times a year x 30M patients, you have $1.8B potential revenue annually. Assume BGMD gets 30% penetration, it would mean $0.6B annual revenue at avg pharma multiples you have $3B market cap or $100PPS. It is also tru that a standard test with exclusive rights could get more than 30% market peentration. I'll let you do the math increasing market share.
    Now I reckon that some of the profits will have to be shared with Abbott, Siemens etc, but it also true that Gal 3 test could be used also in other conditions such as cancer (further confirmatory studies are needed).
    So all in all BGMD potentially could get to $100+ PPS in a few years

    Sentiment: Strong Buy

  • Reply to

    On November 14

    by mstlytrdr 13 hours ago
    staccani staccani 13 hours ago Flag

    They will be selling thru Abbot, Siemens etc etc , no need to have salespeople

    Sentiment: Strong Buy

  • Arterioscler Thromb Vasc Biol. 2015 Jan 22. pii: ATVBAHA.114.304964. [Epub ahead of print]

    CONCLUSION: In high cardiovascular risk patients referred for coronary angiography Gal-3 is a strong independent predictor of cardiovascular death-

    © 2015 American Heart Association, Inc.

    Sentiment: Strong Buy

  • Reply to

    Why BGMD is rising

    by staccani Jan 29, 2015 3:47 PM
    staccani staccani 22 hours ago Flag

    Thanks, good to have you here, we value your input!

    Sentiment: Strong Buy

  • staccani by staccani Jan 29, 2015 3:47 PM Flag

    BGMD is rising on fundamentals

    1) Gal 3 Test efficacy in HF profiling/prediction
    2) No competition
    3) Automation/effectiveness
    4) Blue Chips commercial partnerships
    5) Billions USD target market
    6) Little fixed costs and no debt
    7) Tiny market cap
    8) High Insider's ownership and little float

    All the above, of course make BGMD attractive for potential suitors/buyers

    Sentiment: Strong Buy

  • Pubmed 2014 Aug;47(12):1006-9. doi: 10.1016/j.clinbiochem.2014.06.001. Epub 2014 Jun 10.
    CONCLUSION: Our results demonstrated the clinical validity of the ARCHITECT Gal-3 automated immunoassay for the risk stratification of HF patients. The automation of Gal-3 testing was also cost-effective and might help to preserve hospital budget.

    Sentiment: Strong Buy

  • staccani staccani Jan 29, 2015 2:35 PM Flag

    I would tend to agree with you if you replaced 'buyout price' with 'acquisition evaluation'. The buyout price, assuming there will be a buyout, will be the price at which current shareholders are willing to sell and the prospective buyer is willing to buy. It is also true that normally this price is not very far from the market price (I have never seen a buyout at 10 times current market price). That is why BGMD should not sell now, as I see a BGMD PPS anywhere between $10 and $100 in 2-3 years time

    Sentiment: Strong Buy

  • staccani staccani Jan 29, 2015 2:13 PM Flag

    Of course they cannot mention the ongoing negotiations. That is not what I meant though. I was referring to the approval of automated ARCHITECT test for Gal 3. No mention of BGMD as IP owner

  • Assuming ABT are in negotiations with BGMD majority shareholders, by mentioning BGMD in their 10K, they would have fuelled a further BGMD PPS appreciation. The last thing you want to do if you are trying to buy the company.

    Sentiment: Strong Buy

  • staccani staccani Jan 29, 2015 1:14 PM Flag

    Oh well, if Abbott plans to buy BGMD (assuming the deal is not done yet), then they would certainly not mention BGMD in the PR's/10Q, in order to prevent further PPS appreciation and be forced to make a susbstantially higher offer.

    Sentiment: Strong Buy

  • Food for thought: the automated Gal 3 test, now that is easily availaible, could be usefully used in the general population. Will it become a standard blod test like HLD/LDL, Trigs, etc etc? If so then we are talking about billions of patients and maket cap of USD100B + for BGMD! have a look at the conclusion of the study mentioned below,

    Abstract.  de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL, van der Harst P (University of Groningen). The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272: 55–64.

    CONCLUSIONS
    The results of this study show that plasma galectin-3 levels are correlated with established risk factors for CV disease and mortality in subjects from the general population. Furthermore, plasma galectin-3 levels are higher in women compared with men, and there is a strong gender-specific interaction in the correlations between galectin-3 and other risk factors for CV disease. Increased plasma galectin-3 levels independently predict all-cause mortality. Additional cross-sectional and longitudinal studies are warranted to confirm the link between galectin-3 and risk factors for CV disease and establish its role as a potential risk marker in the prediction of future (CV) events and mortality.

    Sentiment: Strong Buy

  • Not sure if there is enough scientific evidence for that yet. If so, then $100 PPS is peanuts :-)

    Sentiment: Strong Buy

  • This stock could be worth $100+ in 1-2 years time, and although MM's can move the price today or tomorrow they will not be able to stop the steady rise in the months to come as sales start to materialize and ramp up

    Sentiment: Strong Buy

  • Reply to

    someone sold 103,000 shares ......

    by blu10duck Jan 28, 2015 2:42 PM
    staccani staccani Jan 28, 2015 2:58 PM Flag

    who cares? This stock is worth somewhere between $10 and $100, and it will steadily rise in the next few months along with the first sales and the revenue ramp up

    Sentiment: Strong Buy

  • Reply to

    someone sold 103,000 shares ......

    by blu10duck Jan 28, 2015 2:42 PM
    staccani staccani Jan 28, 2015 2:45 PM Flag

    somebody trying to short it. But it would get back in his face like a boomerang as it would need to cover later at huge loss

  • Reply to

    $ 12.01

    by biggensroy Jan 28, 2015 2:11 PM
    staccani staccani Jan 28, 2015 2:18 PM Flag

    Looking ath the potential addressable market, ($2B in HF and who knows how much in all other conditions, with no competition) I think it is reasonable and should Abbott or Siemens would buy BGMD at $12.01 PPS , they would still have a huge return on investment on the acquisition.

    Sentiment: Strong Buy

SVNTQ
0.00190.0000(0.00%)May 30 3:56 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
ImmunoGen, Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST
Amazon.com Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST